Castle Biosciences Inc News - CSTL

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Castle Biosciences Celebrates Skin Cancer Awareness Month

The Company is proud to continue ongoing collaborations with The Sun Bus and The Skin Cancer Foundation, including various activities during the...

Castle Biosciences’ Abstracts at Digestive Disease Week (DDW) Annual Meeting Selected as “Posters of Distinction” by the American Gastroenterological Association (AGA) Institute Council

New data demonstrate the risk-stratification performance and potential of the TissueCypher® Barrett’s Esophagus test to guide risk-aligned...

Castle Biosciences Opens New State-of-the-Art Laboratory in Pittsburgh

The Company expects to double its current workforce in Pittsburgh by the end of 2023 Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving...

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Additional Proxy Soliciting Materials (definitive) (defa14a)

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549SCHEDULE 14A INFORMATIONProxy Statement Pursuant to Section 14(a) of...

Castle Biosciences’ TissueCypher® Barrett's Esophagus Test Receives 2023 MedTech Breakthrough Award for Artificial Intelligence Innovation

This marks the third consecutive year that Castle has been recognized with a MedTech Breakthrough Award for its innovative testing solutions...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Castle Biosciences Inc (CSTL)

Professional-Grade Tools, for Individual Investors.

CSTL News

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Castle Biosciences Celebrates Skin Cancer Awareness Month

Castle Biosciences’ Abstracts at Digestive Disease Week (DDW) Annual Meeting Selected as “Posters of Distinction” by the American Gastroenterological Association (AGA) Institute Council

Castle Biosciences Opens New State-of-the-Art Laboratory in Pittsburgh

Statement of Changes in Beneficial Ownership (4)

Additional Proxy Soliciting Materials (definitive) (defa14a)

Castle Biosciences’ TissueCypher® Barrett's Esophagus Test Receives 2023 MedTech Breakthrough Award for Artificial Intelligence Innovation

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Report of Proposed Sale of Securities (144)

CSTL Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Castle Biosciences Inc (CSTL) News

Castle Biosciences Inc (CSTL)

Professional-Grade Tools, for Individual Investors.

CSTL News

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Castle Biosciences Celebrates Skin Cancer Awareness Month

Castle Biosciences’ Abstracts at Digestive Disease Week (DDW) Annual Meeting Selected as “Posters of Distinction” by the American Gastroenterological Association (AGA) Institute Council

Castle Biosciences Opens New State-of-the-Art Laboratory in Pittsburgh

Statement of Changes in Beneficial Ownership (4)

Additional Proxy Soliciting Materials (definitive) (defa14a)

Castle Biosciences’ TissueCypher® Barrett's Esophagus Test Receives 2023 MedTech Breakthrough Award for Artificial Intelligence Innovation

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Report of Proposed Sale of Securities (144)

CSTL Discussion

Your Recent History